Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
Open accessAbstract
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs.Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs.Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice.Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19.We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.Nonstandard abbreviations used: indoleamine 2,3-dioxygenase (IDO); 1-methyl-D-tryptophan (1MT); mixed leukocyte reaction (MLR); plasmacytoid DC (pDC); regulatory T cell (Treg); T cell receptor (TCR); tumor-draining LN (TDLN). Conflict of interest:The authors have declared that no conflict of interest exists.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In preclinical models, heightened Trp-Kyn-AhR pathway activity is linked to impaired antitumor immunity and tumor growth.
“In preclinical models, heightened activity of the Trp-Kyn-AhR pathway has been linked to impairment of antitumor immunity and tumor growth (16,17).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252 · see citing works
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,124 · see citing works
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,803 · see citing works
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · see citing works
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · see citing works
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D., Shafizadeh, E., Attwood, J., Bondarev, I., Pashine, A., & Mellor, A. (1999) · Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,721 · see citing works
Self-citationModulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375 · see citing works
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5
Nutt, S. L., Heavey, B., Rolink, A. G., & Busslinger, M. (1999) · Nature · doi:10.1038/44076 · Cited by 1,179 · see citing works
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,160 · see citing works
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y.-C., Golumbek, P. T., Ahmadzadeh, M., Jaffee, E. M., Pardoll, D. M., & Levitsky, H. I. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,159 · see citing works
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133 · see citing works
Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060 · see citing works
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058 · see citing works
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R. E., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028 · see citing works
Self-citationT cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022 · see citing works
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin‐Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter‐Dambuyant, C., Vicari, A. P., O’Garra, A., Biron, C. A., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,021 · see citing works
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · see citing works
Terness, P., Bauer, T. M., Röse, L., Dufter, C., Watzlik, A., Simon, H., & Opelz, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020052 · Cited by 939 · see citing works
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth‐Dreese, F. A., Dellemijn, T. A. M., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 927 · see citing works
Pfefferkorn, E. (1984) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.81.3.908 · Cited by 870 · see citing works
Tolerance, DCs and tryptophan: much ado about IDO
Grohmann, U. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00072-3 · Cited by 766 · see citing works
A fresh look at tumor immunosurveillance and immunotherapy
Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001) · Nature Immunology · doi:10.1038/86297 · Cited by 747 · see citing works
Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W., & Young, H. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3596 · Cited by 742 · see citing works
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K. F., Sotomayor, E. M., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D. M., & Levitsky, H. I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 702 · see citing works
Clinical significance of defective dendritic cell differentiation in cancer.
Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699 · see citing works
Iwasaki, A., & Kelsall, B. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.2.229 · Cited by 636 · see citing works
Karsunky, H., Mérad, M., Cozzio, A., Weissman, I. L., & Manz, M. G. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030323 · Cited by 594 · see citing works
Models of T cell anergy: is there a common molecular mechanism?
Schwartz, R. H. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.1.1 · Cited by 568 · see citing works
Regulation of B Lymphocyte Responses to Foreign and Self-Antigens by the CD19/CD21 Complex
Fearon, D. T., Carroll, M. C., & Carroll, M. C. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.393 · Cited by 529 · see citing works
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
Ochsenbein, A. F., Sierro, S. R., Odermatt, B., Pericin, M., Karrer, U. W., Hermans, J., Hemmi, S., Hengartner, H., & Zinkernagel, R. M. (2001) · Nature · doi:10.1038/35082583 · Cited by 492 · see citing works
Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K. G., Hansen, A. M., Koni, P. A., Iwashima, M., & Munn, D. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1652 · Cited by 457 · see citing works
Self-citationMunn, D. H., Sharma, M. D., & Mellor, A. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4100 · Cited by 453 · see citing works
Self-citationBronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M. L., Hwu, P., & Restifo, N. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5728 · Cited by 404 · see citing works
O’Keeffe, M. A., Hochrein, H., Vremec, D., Caminschi, I., Miller, J. L., Anders, E. M., Wu, L., Lahoud, M. H., Henri, S., Scott, B., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021031 · Cited by 368 · see citing works
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A. B., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 366 · see citing works
Self-citationEradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy
Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., Shiku, H., Schreiber, R. D., & Allen, P. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00026-1 · Cited by 358 · see citing works
Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses
Mellor, A. L., Keskin, D. B., Johnson, T. S., Chandler, P., & Munn, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3771 · Cited by 348 · see citing works
Self-citationVicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343 · see citing works
Nutt, S. L., Morrison, A. M., Dörfler, P., Rolink, A. G., & Busslinger, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.8.2319 · Cited by 315 · see citing works
Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., & Ohashi, P. S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.645 · Cited by 309 · see citing works
Reversion of B Cell Commitment upon Loss of Pax5 Expression
Mikkola, I., Heavey, B., Horcher, M., & Busslinger, M. (2002) · Science · doi:10.1126/science.1067518 · Cited by 291 · see citing works
Powell, J. D., Lerner, C. G., & Schwartz, R. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2775 · Cited by 290 · see citing works
Shrikant, P. A., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 284 · see citing works
Munn, D. H., & Mellor, A. L. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.11.003 · Cited by 256 · see citing works
Self-citationClonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation
DeSilva, D. R., Urdahl, K. B., & Jenkins, M. K. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.10.3261 · Cited by 252 · see citing works
Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+ dendritic cells
Fallarino, F., Vacca, C., Orabona, C., Belladonna, M. L., Bianchi, R., Marshall, B., Keskin, D. B., Mellor, A. L., Fioretti, M. C., Grohmann, U., et al. (2002) · International Immunology · doi:10.1093/intimm/14.1.65 · Cited by 246 · see citing works
Self-citationYang, H. H., Yamagata, N., Yadav, R., Brandon, S., Courtney, R., Morrow, J. D., Shyr, Y., Boothby, M. R., Joyce, S., Carbone, D. P., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16492 · Cited by 246 · see citing works
Rissoan, M., Duhen, T., Bridon, J., Bendriss‐Vermare, N., Péronne, C., Vis, B. D. S., Brière, F., & Bates, E. E. M. (2002) · Blood · doi:10.1182/blood-2002-02-0638 · Cited by 244 · see citing works
Martı́n, P., del Hoyo, G. M., Anjuère, F., Fernández-Arias, C., Hernández‐Vargas, H., Fernández-L, A., Parrillas, V., & Ardavı́n, C. (2002) · Blood · doi:10.1182/blood.v100.2.383 · Cited by 237 · see citing works
Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y., & Schreiber, H. W. (2002) · Immunity · doi:10.1016/s1074-7613(02)00480-6 · Cited by 234 · see citing works
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes
Mattei, S., Colombo, M. P., Melani, C. C., Silvani, A., Parmiani, G., & Herlyn, M. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560617 · Cited by 233 · see citing works
Dendritic Cells in Immunity and Tolerance—Do They Display Opposite Functions?
Moser, M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00182-1 · Cited by 229 · see citing works
Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis
Sakurai, K., Zou, J.-P., Tschetter, J. R., Ward, J. M., & Shearer, G. M. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00176-5 · Cited by 227 · see citing works
Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice
Gurtner, G. J., Newberry, R. D., Schloemann, S. R., McDonald, K. G., & Stenson, W. F. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.08.031 · Cited by 225 · see citing works
Sotomayor, E. M., Borrello, I., Rattis, F., Cuenca, A. G., Abrams, J., Staveley-O’Carroll, K. F., & Levitsky, H. I. (2001) · Blood · doi:10.1182/blood.v98.4.1070 · Cited by 211 · see citing works
A Defect in Tryptophan Catabolism Impairs Tolerance in Nonobese Diabetic Mice
Grohmann, U., Fallarino, F., Bianchi, R., Orabona, C., Vacca, C., Fioretti, M. C., & Puccetti, P. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030633 · Cited by 209 · see citing works
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
Furumoto, K., Soares, L. R. B., Engleman, E. G., & Mérad, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19762 · Cited by 206 · see citing works
The Lymphoid Past of Mouse Plasmacytoid Cells and Thymic Dendritic Cells
Corcoran, L. M., Ferrero, I., Vremec, D., Lucas, K., Waithman, J. C., O’Keeffe, M. A., Wu, L., Wilson, A., & Shortman, K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4926 · Cited by 201 · see citing works
Tryptophan Catabolism and Regulation of Adaptive Immunity
Mellor, A. L., & Munn, D. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.5809 · Cited by 200 · see citing works
Self-citationWick, M., Dubey, P., Koeppen, H., Siegel, C., Fields, P. E., Chen, L., Bluestone, J. A., & Schreiber, H. W. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.229 · Cited by 195 · see citing works
Bodaghi, B., Goureau, O., Zipeto, D., Laurent, L., Virelizier, J. L., & Michelson, S. (1999) · PubMed · Cited by 180 · see citing works
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
Furumoto, K., Soares, L., Engleman, E. G., & Merad, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419762 · Cited by 180 · see citing works
Melief, C. J. M. (2003) · European Journal of Immunology · doi:10.1002/eji.200324341 · Cited by 177 · see citing works
Bodaghi, B., Goureau, O., Zipeto, D., Laurent, L., Virelizier, J., & Michelson, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.957 · Cited by 154 · see citing works
CD40L Blockade Prevents Autoimmune Diabetes by Induction of Bitypic NK/DC Regulatory Cells
Homann, D., Jahreis, A., Wolfe, T., Hughes, A. C., Coon, B., van Stipdonk, M. J. B., Prilliman, K. R., Schoenberger, S. P., & von Herrath, M. G. (2002) · Immunity · doi:10.1016/s1074-7613(02)00290-x · Cited by 148 · see citing works
Zélénika, D., Adams, E., Mellor, A. L., Simpson, E., Chandler, P., Stockinger, B., Waldmann, H., & Cobbold, S. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1868 · Cited by 143 · see citing works
Self-citationTumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance
Nguyen, L. T., Elford, A. R., Murakami, K., Garza, K. M., Schoenberger, S. P., Odermatt, B., Speiser, D. E., & Ohashi, P. S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20010032 · Cited by 128 · see citing works
Scott, D. M., Addey, C., Ellis, P., James, E., Mitchell, M. J., Saut, N., Jurčević, S., & Simpson, E. (2000) · Immunity · doi:10.1016/s1074-7613(00)80221-6 · Cited by 124 · see citing works
Adams, O., Besken, K., Oberdörfer, C., MacKenzie, C. R., Takikawa, O., & Däubener, W. (2004) · Journal of Virology · doi:10.1128/jvi.78.5.2632-2636.2004 · Cited by 119 · see citing works
Cuenca, A. G., Cheng, F., Wang, H., Brayer, J. B., Horna, P., Gu, L., Bien, H., Borrello, I., Levitsky, H. I., & Sotomayor, E. M. (2003) · PubMed · Cited by 117 · see citing works
A Common Pathway for Dendritic Cell and Early B Cell Development
Izon, D. J., Rudd, K., DeMuth, W., Pear, W. S., Clendenin, C. J., Lindsley, R. C., & Allman, D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1387 · Cited by 114 · see citing works
Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma
Lee, J. R., Dalton, R. R., Messina, J. L., Sharma, M. D., Smith, D., Burgess, R. E., Mazzella, F. M., Antonia, S. J., Mellor, A. L., & Munn, D. H. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000090158.68852.d1 · Cited by 114 · see citing works
Self-citationGupta, S., Carlin, J. M., Pyati, P. S., Dai, W., Pfefferkorn, E. R., & Murphy, M. J. (1994) · Infection and Immunity · doi:10.1128/iai.62.6.2277-2284.1994 · Cited by 114 · see citing works
Borrello, I., Sotomayor, E. M., Cooke, S., & Levitsky, H. I. (1999) · Human Gene Therapy · doi:10.1089/10430349950017347 · Cited by 110 · see citing works
FcεRI Induces the Tryptophan Degradation Pathway Involved in Regulating T Cell Responses
von Bubnoff, D., Matz, H., Frahnert, C., Rao, M. L., Hanau, D., de la Salle, H., & Bieber, T. R. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.1810 · Cited by 98 · see citing works
CD19+ pro-B cells can give rise to dendritic cells in vitro.
Björck, P., & Kincade, P. W. (1998) · PubMed · Cited by 95 · see citing works
Grohmann, U., Bianchi, R., Belladonna, M. L., Silla, S., Fallarino, F., Fioretti, M. C., & Puccetti, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1357 · Cited by 93 · see citing works
Pardoll, D. M. (2001) · Nature · doi:10.1038/35082676 · Cited by 87 · see citing works
Cutting Edge: CD19+ Pro-B Cells Can Give Rise to Dendritic Cells In Vitro
Björck, P., & Kincade, P. W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.5795 · Cited by 83 · see citing works
Regulation of tumour immunity by CD25+ T cells
Gallimore, A., & Sakaguchi, S. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01471.x · Cited by 78 · see citing works
Yu, P., Spiotto, M. T., Lee, Y., Schreiber, H. W., & Fu, Y. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021804 · Cited by 75 · see citing works
Nelson, D. J., Mukherjee, S., Bundell, C. S., Fisher, S. A., van Hagen, D., & Robinson, B. W. S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5557 · Cited by 65 · see citing works
Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation
Spiotto, M. T., Fu, Y., & Schreiber, H. (2003) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.09.018 · Cited by 54 · see citing works
Cytokine Profiles of Sentinel Lymph Nodes Draining the Primary Melanoma
Leong, S. P. L. (2002) · Annals of Surgical Oncology · doi:10.1245/aso.2002.9.1.82 · Cited by 53 · see citing works
Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo
Tarazona, R., Sponaas, A. M., Mavria, G., Zhou, M., Schulz, R., Tomilnson, P., Antoniou, J., & Mellor, A. L. (1996) · International Immunology · doi:10.1093/intimm/8.3.351 · Cited by 15 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works
A guide to immunometabolism for immunologists
O'Neill, L. A. J., Kishton, R. J., & Rathmell, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.70 · Cited by 3,315 · see citing works
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341 · see citing works
Self-citationRegulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · see citing works
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,659 · see citing works
IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors
Liu, Y.-J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115633 · Cited by 1,618 · see citing works
von Büdingen, H. ‐., Palanichamy, A., Lehmann‐Horn, K., Michel, B., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,475 · see citing works
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,275 · see citing works
Self-citationThe multifaceted biology of plasmacytoid dendritic cells
Swiecki, M. K., & Colonna, M. (2015) · Nature reviews. Immunology · doi:10.1038/nri3865 · Cited by 1,131 · see citing works
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,074 · see citing works
Self-citationIDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,054 · see citing works
Self-citationFallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,042 · see citing works
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037 · see citing works
Self-citationTargeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997 · see citing works
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2016) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 926 · see citing works
Sharma, M. D., Baban, B., Chandler, P., Hou, D., Singh, N., Yagita∥, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 791 · see citing works
Self-citationGhiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, É., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776 · see citing works
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E. M., & Pardoll, D. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 690 · see citing works
Amino Assets: How Amino Acids Support Immunity
Kelly, B. L., & Pearce, E. L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.010 · Cited by 653 · see citing works
Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 633 · see citing works
Self-citationBrandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614 · see citing works
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 608 · see citing works
Yu, J., Du, W., Fang, Y., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 608 · see citing works
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 602 · see citing works
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · see citing works
Hou, D., Muller, A. J., Sharma, M. D., DuHadaway, J. B., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586 · see citing works
Self-citationWainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A. L., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 571 · see citing works
Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?
Guerin, L. R., Prins, J. R., & Robertson, S. A. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp004 · Cited by 506 · see citing works
Tolerogenic dendritic cells: cytokine modulation comes of age
Rutella, S., Danese, S., & Leone, G. G. M. (2006) · Blood · doi:10.1182/blood-2006-03-006403 · Cited by 490 · see citing works
Duluc, D., Delneste, Y., Tan, F., Moles, M., Grimaud, L., Lenoir, J., Preisser, L., Anegón, I., Catala, L., Ifrah, N., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072587 · Cited by 490 · see citing works
Type I Interferon in Chronic Virus Infection and Cancer
Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 490 · see citing works
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Holmgaard, R., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 483 · see citing works
Self-citationNanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente‐Casares, X., Tsai, S. J., Yang, Y., & Santamaría, P. (2014) · ACS Nano · doi:10.1021/nn5062029 · Cited by 472 · see citing works
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 471 · see citing works
Sinha, P., Clements, V. K., & Ostrand‐Rosenberg, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.636 · Cited by 461 · see citing works
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation
Puccetti, P., & Grohmann, U. (2007) · Nature reviews. Immunology · doi:10.1038/nri2163 · Cited by 457 · see citing works
Chen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5396 · Cited by 453 · see citing works
Self-citationInhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H., Opelz, G., & Terness, P. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2639 · Cited by 421 · see citing works
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413 · see citing works
Sharma, M. D., Hou, D., Liu, Y., Koni, P. A., Metz, R. A., Chandler, P., Mellor, A. L., He, Y., & Munn, D. H. (2009) · Blood · doi:10.1182/blood-2008-12-195354 · Cited by 406 · see citing works
Self-citationIndoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 399 · see citing works
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 398 · see citing works
Swiecki, M., & Colonna, M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00881.x · Cited by 397 · see citing works
Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V., Bonanno, G., Rutella, S., Durelli, I., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036863 · Cited by 396 · see citing works
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
Bronte, V., Kasic, T., Gri, G., Gallana, K., Borsellino, G., Marigo, I., Battistini, L., Iafrate, M., Prayer‐Galetti, T., Pagano, F. C., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042028 · Cited by 394 · see citing works
Mougiakakos, D., Choudhury, A., Lladser, Á., Kiessling, R. W., & Johansson, C. C. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07003-x · Cited by 392 · see citing works
Combination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 379 · see citing works
Matteoli, G., Mazzini, E., Iliev, I. D., Mileti, E., Fallarino, F., Puccetti, P., Chieppa, M., & Rescigno, M. (2010) · Gut · doi:10.1136/gut.2009.185108 · Cited by 377 · see citing works
Plasmacytoid Dendritic Cells Mediate Oral Tolerance
Goubier, A., Dubois, B., Gheit, H., Joubert, G., Villard‐Truc, F., Asselin‐Paturel, C., Trinchieri, G., & Kaiserlian, D. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.017 · Cited by 376 · see citing works
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lü, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Cañadas, I., Tian, Y., Niu, X., Wang, Y. Z., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 376 · see citing works
Immune modulation by mesenchymal stem cells
Rasmusson, I. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.019 · Cited by 374 · see citing works
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta-Guha, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 373 · see citing works
Thomas, S., Izard, J., Walsh, E. K., Batich, K. A., Chongsathidkiet, P., Clarke, G. A., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 369 · see citing works
Théate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J., Hervé, C., Gutierrez-Roelens, I., Marbaix, É., Sempoux, C. L., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 366 · see citing works
Ge, W., Jiang, J., Arp, J., Liu, W., Garcia, B. M., & Wang, H. (2010) · Transplantation · doi:10.1097/tp.0b013e3181fed001 · Cited by 350 · see citing works
Twelve immunotherapy drugs that could cure cancers
Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 339 · see citing works
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336 · see citing works
Rossi, M., & Young, J. W. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1373 · Cited by 335 · see citing works
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity
du Bois, H., Heim, T. A., & Lund, A. W. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg3551 · Cited by 334 · see citing works
Creating immune privilege: active local suppression that benefits friends, but protects foes
Mellor, A. L., & Munn, D. H. (2007) · Nature reviews. Immunology · doi:10.1038/nri2233 · Cited by 327 · see citing works
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Sautès‐Fridman, C., Tartour, É., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 327 · see citing works
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325 · see citing works
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Lemos, H. D. P., Mohamed, E. T., Huang, L., Ou, R., Pacholczyk, G. A., Arbab, A. S., Munn, D. H., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325 · see citing works
Self-citationEmerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 316 · see citing works
Targeting metabolism to regulate immune responses in autoimmunity and cancer
Patel, C. H., Leone, R. D., Horton, M. R., & Powell, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0032-5 · Cited by 307 · see citing works
Löb, S., Königsrainer, A., Zieker, D., Brücher, B. L. D. M., Rammensee, H., Opelz, G., & Terness, P. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0513-6 · Cited by 305 · see citing works
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 302 · see citing works
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292 · see citing works
Boasso, A., Herbeuval, J., Hardy, A. W., Anderson, S. A., Dolan, M. J., Fuchs, D., & Shearer, G. M. (2006) · Blood · doi:10.1182/blood-2006-07-034785 · Cited by 286 · see citing works
Zhao, F. L., Xiao, C., Evans, K. S., Theivanthiran, T., DeVito, N. C., Holtzhausen, A., Liu, J., Liu, X., Boczkowski, D., Nair, S. K., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.004 · Cited by 286 · see citing works
Vermaelen, K. Y., & PAUWELS, R. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1384so · Cited by 278 · see citing works
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276 · see citing works
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Ball, H. J., Yuasa, H. J., Austin, C., Weiser, S., & Hunt, N. H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.005 · Cited by 275 · see citing works
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H. D. P., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0106-z · Cited by 275 · see citing works
Self-citationIndoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
Prendergast, G. C., Malachowski, W. P., Mondal, A., Scherle, P., & Muller, A. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 274 · see citing works
Macri, C., Pang, E. S., Patton, T., & O’Keeffe, M. A. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.12.009 · Cited by 274 · see citing works
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Krüse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 268 · see citing works
Pao, L. I., Lam, K., Henderson, J., Kutok, J. L., Alimzhanov, M. B., Nitschke, L., Thomas, M. L., Neel, B. G., & Rajewsky, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.04.016 · Cited by 264 · see citing works
Reddy, P. R., Sun, Y., Toubai, T., Duran‐Struuck, R., Clouthier, S. G., Weisiger, E., Maeda, Y., Tawara, I., Krijanovski, O. I., Gatza, E., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34712 · Cited by 264 · see citing works
Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J. D., Munn, D. H., & Young, J. W. (2009) · Blood · doi:10.1182/blood-2008-11-191197 · Cited by 264 · see citing works
Self-citationTargeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1929 · Cited by 263 · see citing works
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2008) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259 · see citing works
The tumor‐draining lymph node as an immune‐privileged site
Munn, D. H., & Mellor, A. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00444.x · Cited by 251 · see citing works
Self-citationTumor masses support naive T cell infiltration, activation, and differentiation into effectors
Thompson, E. D., Enriquez, H. L., Fu, Y., & Engelhard, V. H. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092454 · Cited by 250 · see citing works
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N. K., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 247 · see citing works
Muller, A. J., Sharma, M. D., Chandler, P., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J. P. S., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 242 · see citing works
Self-citationIno, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., Nawa, A., Nagasaka, T., Takikawa, O., & Kikkawa, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4144 · Cited by 241 · see citing works
Lurquin, C., Lethé, B., Plaen, E. D., Corbière, V., Théate, I., van Baren, N., Coulie, P. G., & Boon, T. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041378 · Cited by 239 · see citing works
Improving T Cell Therapy for Cancer
Leen, A. M., Rooney, C. M., & Foster, A. E. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141527 · Cited by 238 · see citing works
von Bergwelt‐Baildon, M. S., Popov, A., Šarić, T., Chemnitz, J. M., Claßen, S., Stoffel, M. S., Fiore, F., Roth, U., Beyer, M., Debey, S., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3507 · Cited by 237 · see citing works
Weiner, J. M., Parida, S. K., Maertzdorf, J., Black, G. F., Repsilber, D., Telaar, A., Mohney, R. P., Arndt-Sullivan, C., Ganoza, C. A., Fae, K. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040221 · Cited by 237 · see citing works
Role of indoleamine 2,3-dioxygenase in health and disease
Yeung, A. W. S., Terentis, A. C., King, N. J. C., & Thomas, S. R. (2015) · Clinical Science · doi:10.1042/cs20140392 · Cited by 235 · see citing works
Regulatory T cells in autoimmune neuroinflammation
Kleinewietfeld, M., & Hafler, D. A. (2014) · Immunological Reviews · doi:10.1111/imr.12169 · Cited by 230 · see citing works
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
van Baren, N., & den Eynde, B. J. V. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 230 · see citing works
Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment
Gajewski, T. F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0892 · Cited by 230 · see citing works
Cancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 229 · see citing works
Croci, D. O., Fluck, M. F. Z., Rico, M. J., Matar, P., Rabinovich, G. A., & Scharovsky, O. G. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0343-y · Cited by 228 · see citing works
Manches, O., Munn, D. H., Fallahi, A., Lifson, J. D., Chaperot, L., Plumas, J., & Bhardwaj, N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34823 · Cited by 228 · see citing works
Self-citation
- Authors
- Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L.
- Affiliations
- Augusta University (US)
- University of South Florida (US)
- Corresponding author
- Munn, David H.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-15
- Volume
- 114
- Issue
- 2
- Pages
- 280-290
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2143565660
- Cited by
- 852
- References
- 85
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 32 · 2021: 37 · 2020: 34 · 2019: 29 · 2018: 31 · 2017: 40 · 2016: 27 · 2015: 45 · 2014: 38 · 2013: 53 · 2012: 39
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Carlos and Marguerite Mason Trust
- National Institutes of Health
- National Cancer Institute (R01CA096651, R01 CA103220)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD041187)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- indoleamine 2,3-dioxygenase, plasmacytoid dendritic cells, tumor-draining lymph nodes, immunosuppression, T cell anergy, tumor antigen presentation, CD19, 1-methyl-D-tryptophan, antitumor immunity, regulatory T cells, mixed lymphocyte reaction
- MeSH terms
- Animals, Antigen-Presenting Cells, Dendritic Cells, Female, Humans, Immunosuppression Therapy, Lymph Nodes, Lymphocyte Activation, Mice, Inbred Strains, Neoplasms, Random Allocation, T-Lymphocytes, Tryptophan Oxygenase, Survival Rate, Mice, Knockout, Antigens, CD19, Adoptive Transfer, CD11c Antigen, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
